Amiodarone and the risk of cancer: A nationwide population-based study

Cancer

Volumn 119, Issue 9, 2013, Pages 1699-1705

  Su, Vincent Yi Fong ^a   Hu, Yu Wen ^a,b   Chou, Kun Ta ^a,b   Ou, Shuo Ming ^a   Lee, Yu Chin ^a,b   Lin, Elizabeth Ya Hsuan ^c   Chen, Tzeng Ji ^a,b   Tzeng, Cheng Hwai ^a,b   Liu, Chia Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

amiodarone; cancer; lung cancer; malignancy; thyroid cancer

Indexed keywords

AMIODARONE;

ADULT; AGE; AGED; ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BONE CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLON CANCER; COMORBIDITY; DATA BASE; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GENDER; HEAD AND NECK CANCER; HEALTH INSURANCE; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SKIN CANCER; SOFT TISSUE CANCER; STOMACH CANCER; TAIWAN; THYROID CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84876667157     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27881     Document Type: Article

References (30)

1. Gillis AM, Kates RE,. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet. 1984; 9: 375-403.
2. Jonckheer MH,. Amiodarone and the thyroid gland. A review. Acta Cardiol. 1981; 36: 199-205.
3. Alinovi A, Reverberi C, Melissari M, Gabrielli M,. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. J Am Acad Dermatol. 1985; 12: 563-566.
4. Brambilla G, Martelli A,. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat Res. 2009; 681: 209-229.
5. US Food and Drug Administration. Medication Guide: Amiodarone HCl. NDA 18-972/S-038/039. Washington, DC: US Food and Drug Administration; 2004. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/018972s038s039lbl.pdf. Accessed October 21, 2012.
6. Arnon R, Raz I, Chajek-Shaul T, Berkman N, Fields S, Bar-On H,. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest. 1988; 93: 425-427.
7. Piccione W Jr, Faber LP, Rosenberg MS,. Amiodarone-induced pulmonary mass. Ann Thorac Surg. 1989; 47: 918-919.
8. Azzam I, Tov N, Elias N, Naschitz JE,. Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J. 2006; 82: 73-75.
9. Rodriguez-Garcia JL, Garcia-Nieto JC, Ballesta F, Prieto E, Villanueva MA, Gallardo J,. Pulmonary mass and multiple lung nodules mimicking a lung neoplasm as amiodarone-induced pulmonary toxicity. Eur J Intern Med. 2001; 12: 372-376.
10. Patel P, Honeybourne D, Watson RD,. Amiodarone-induced pulmonary toxicity mimicking metastatic lung disease. Postgrad Med J. 1987; 63: 393-394.
11. Kimura T, Kuramochi S, Katayama T, et al. Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: diagnostic pitfall and new findings. Pathol Int. 2008; 58: 657-663.
12. Facchini G, Forte S, Podda P, Piro F, Carlone S,. Pulmonary masses in a patient with blue-gray cutaneous hyperpigmentation. Eur Rev Med Pharmacol Sci. 2008; 12: 113-116.
13. Cattaneo F,. Type II amiodarone-induced thyrotoxicosis and concomitant papillary cancer of the thyroid. Eur J Endocrinol. 2000; 143: 823-824.
14. Saad A, Falciglia M, Steward DL, Nikiforov YE,. Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. Arch Pathol Lab Med. 2004; 128: 807-810.
15. Inaba H, Suzuki S, Takeda T, Kobayashi S, Akamizu T, Komatsu M,. Amiodarone-induced thyrotoxicosis with thyroid papillary cancer in multinodular goiter: case report. Med Princ Pract. 2012; 21: 190-192.
16. Monk B,. Amiodarone-induced photosensitivity and basal-cell carcinoma. Clin Exp Dermatol. 1990; 15: 319-320.
17. Monk BE,. Basal cell carcinoma following amiodarone therapy. Br J Dermatol. 1995; 133: 148-149.
18. Hall MA, Annas A, Nyman K, Talme T, Emtestam L,. Basalioma after amiodarone therapy-not only in Britain. Br J Dermatol. 2004; 151: 932-933; author reply 933.
19. Maoz KB, Dvash S, Brenner S, Brenner S,. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol. 2009; 48: 1398-1400.
20. Tsan YT, Lee CH, Wang JD, Chen PC,. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012; 30: 623-630.
21. Han YY, Youk AO, Sasser H, Talbott EO,. Cancer incidence among residents of the Three Mile Island accident area: 1982-1995. Environ Res. 2011; 111: 1230-1235.
22. Suissa S,. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008; 167: 492-499.
23. De Neve W, Fortan L, Storme G,. Increased acute mucosal and cutaneous radiation toxicity in two patients taking amiodarone. Int J Radiat Oncol Biol Phys. 1992; 22: 224.
24. Piccini JP, Berger JS, O'Connor CM,. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009; 30: 1245-1253.
25. Araki R, Yukawa E, Nakashima MN, et al. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients. Ther Drug Monit. 2011; 33: 750-756.
26. Smyrk TC, Goellner JR, Brennan MD, Carney JA,. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol. 1987; 11: 197-204.
27. Trip MD, Wiersinga W, Plomp TA,. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991; 91: 507-511.
28. Harjai KJ, Licata AA,. Effects of amiodarone on thyroid function. Ann Intern Med. 1997; 126: 63-73.
29. Mellemgaard A, From G, Jorgensen T, Johansen C, Olsen JH, Perrild H,. Cancer risk in individuals with benign thyroid disorders. Thyroid. 1998; 8: 751-754.
30. Stahli BE, Schwab S,. Amiodarone-induced skin hyperpigmentation. QJM. 2011; 104: 723-724.